Many Strategic Possibilities in Prostrate Cancer R&D.

February 7 2004--Research and Markets announces the addition of this exciting new report entitled "Analysis of Prostate Cancer R&D: The Complete Guide" to its offerings.

According to the American Cancer Society, after skin cancer, prostate cancer is the most common type of cancer found in American men and is the second leading cause of cancer deaths in men, exceeded only by lung cancer.

Analysis of Prostate Cancer R&D - the Complete Guide offers a unique tool for analysing the vast amount of strategic possibilities that have emerged in prostate cancer R&D.This tool provides an immense amount of structured information. Innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. "Analysis of Prostate Cancer R&D - the Complete Guide" gives you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current prostate cancer pipeline.

For a complete index of this report click on http://www.researchandmarkets.com/reports/44928

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com





This article courtesy of http://www.childrenscancersociety.com.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.

Submit Your Article